---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-260923"
form_type: "8-K"
ticker: "NAMS"
cik: "0001936258"
company_name: "NewAmsterdam Pharma Co N.V."
filed_at: "2024-11-18T23:59:59+00:00"
generated_at: "2026-05-29T23:16:27.359696+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# NewAmsterdam Pharma reports Phase 3 BROOKLYN trial: LDL-C reduced 36.3% vs placebo at day 84, Lp(a) reduced 45.9%

## Summary
- LDL-C mean reduction vs placebo 36.3% at day 84 (p<0.0001), sustained at 41.5% at day 365.
- Lp(a) mean reduction vs placebo 45.9% at day 84; total LDL particles reduced 52.5% at day 180.
- Safety comparable to placebo; discontinuation rate 7.6% for obicetrapib vs 14.4% for placebo.
- Trial enrolled 354 HeFH patients; mean baseline LDL-C 123 mg/dL despite high statin use (79%) and ezetimibe (54%).
- Data presented at AHA 2024; topline from TANDEM and BROADWAY studies expected Q4 2024.

## SEC filing metadata
- accession: 0001193125-24-260923
- form_type: 8-K
- ticker: NAMS
- cik: 0001936258
- company_name: NewAmsterdam Pharma Co N.V.
- filed_at: 2024-11-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1936258/000119312524260923/0001193125-24-260923-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1936258/000119312524260923/d840591d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-260923
- JSON: https://secwatch.observer/filing/0001193125-24-260923.json
- Plain text: https://secwatch.observer/filing/0001193125-24-260923.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.